Pharmacokinetics and safety of intravenous oseltamivir in infants and children in open-label studies

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 7, 2015, Pages 531-540

  Muñoz, Flor M ^a   Anderson, Evan J ^b   Deville, Jaime G ^c   Clinch, Barry ^d   Kamal, Mohamed A ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

^e Roche Pharmaceutical Research and Early Development   (United States)

Author keywords

Influenza; Intravenous; Oseltamivir; Pediatric

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; APPLICATION SITE ERYTHEMA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HOSPITALIZED CHILD; HUMAN; HYPOKALEMIA; HYPOTENSION; IC50; INFANT; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA B; INJECTION SITE ERYTHEMA; INJECTION SITE EXTRAVASATION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NEWBORN; NONHUMAN; OPEN STUDY; PHENOTYPE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEINURIA; PULMONARY HYPERTENSION; RASH; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIDE EFFECT; SINUS BRADYCARDIA; THROMBOPHLEBITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD; VIRUS SHEDDING; AGE; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HOSPITALIZATION; INFLUENZA, HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORTHOMYXOVIRIDAE; PATHOGENICITY; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; INFUSIONS, INTRAVENOUS; MALE; ORTHOMYXOVIRIDAE; OSELTAMIVIR; PATIENT SAFETY; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; VIRUS SHEDDING;

EID: 84936767994     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202307     Document Type: Article

References (16)

1. Ampofo K, Gesteland PH, Bender J, Mills M, Daly J, Samore M, Byington C, Pavia AT, Srivastava R. Epidemiology, complications, and cost of hospitalization in children with laboratory-confirmed influenza infection. Pediatrics. 2006; 118: 2409-2417. CrossRef PubMed
2. Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, Likos AM, Posey DL, Klimov A, Lindstrom SE, Balish A, Medina MJ, Wallis TR, Guarner J, Paddock CD, Shieh WJ, Zaki SR, Sejvar JJ, Shay DK, Harper SA, et al Influenza Special Investigations Team. Influenza-associated deaths among children in the United States, 2003 - 2004. N Engl J Med. 2005; 353: 2559-2567. CrossRef PubMed
3. Chaves SS, Perez A, Farley MM, Miller L, Schaffner W, Lindegren ML, Sharangpani R, Meek J, Yousey-Hindes K, Thomas A, Boulton R, Baumbach J, Hancock EB, Bandyopadhyay AS, Lynfield R, Morin C, Zansky SM, Reingold A, Bennett NM, Ryan P, et al Influenza Hospitalization Surveillance Network. The burden of influenza hospitalizations in infants from 2003 to 2012, United States. Pediatr Infect Dis J. 2014; 33: 912-919. PubMed
4. Loughlin J, Poulios N, Napalkov P, Wegmüller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics. 2003; 21: 273-283. CrossRef PubMed
5. Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA, Iwane MK, Snively BM, Suerken CK, Hall CB, Weinberg GA, Chaves SS, Zhu Y, McNeal MM, Bridges CB. The burden of influenza in young children, 2004-2009. Pediatrics. 2013; 131: 207-216. CrossRef PubMed
6. Centers for Disease Control and Prevention. Seasonal influenza (flu). Influenza antiviral medications: summary for clinicians. Updated March 2014. Accessed on 04.06.2014 at http://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
7. World Health Organization. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. February 2010. Accessed on 04.06.14 at http://www.who.int/csr/resources/publications/swineflu/h1n1-use-antivirals-20090820/en/.
8. Wildschut ED, de Hoog M, Ahsman MJ, Tibboel D, Osterhaus AD, Fraaij PL. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS ONE. 2010; 5: e10938. CrossRef PubMed
9. Eyler RF, Klein KC, Mueller BA. The pharmacokinetics of oseltamivir and oseltamivir carboxylate in a critically ill pediatric patient receiving extracorporeal membrane oxygenation and continuous venovenous hemodialysis. J Pediatr Pharmacol Ther. 2012; 17: 173-176. CrossRef PubMed
10. Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J. 2010; 29: 495-498. PubMed
11. Pannaraj PS, Tam B, Akan D. Oseltamivir treatment and prophylaxis in a neonatal intensive care unit during a 2009 H1N1 influenza outbreak. J Perinatol. 2011; 31: 487-493. CrossRef PubMed
12. Kimberlin DW, Acosta EP, Prichard MN, Sánchez PJ, Ampofo K, Lang D, Ashouri N, Vanchiere JA, Abzug MJ, Abughali N, Caserta MT, Englund JA, Sood SK, Spigarelli MG, Bradley JS, Lew J, Michaels MG, Wan W, Cloud G, Jester P, et al National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza. J Infect Dis. 2013; 207: 709-720. CrossRef PubMed
13. Rath B, Clinch B, Abadir D, Brzostek J, Chappey C, Charoin-Pannier A, Klumpp K, Niranjan V, Tong X, Wollenhaupt M, Rayner CR. A prospective, open-label study of the pharmacokinetics, safety and pharmacodynamics of oseltamivir in infants <1 year with influenza. A-1245. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 09.09.12-12.09.12, San Francisco.
14. Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1 - 5 years. Eur J Clin Pharmacol. 2003; 59: 411-415. CrossRef PubMed
15. Kamal MA, Acosta EP, Kimberlin DW, Gibiansky L, Jester P, Niranjan V, Rath B, Clinch B, Sánchez PJ, Ampofo K, Whitley R, Rayner CR. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Clin Pharmacol Ther. 2014; 96: 380-389. CrossRef PubMed
16. Várkonyi I, Chappey C, Giraudon M, Burleigh L. A part-randomized study of intravenous oseltamivir in adolescents and adults. Eur J Clin Microbiol Infect Dis. 2015; epub ahead of print. CrossRef PubMed